• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    1/7/22 12:56:21 PM ET
    $ABSI
    $ALGS
    $ANIX
    $ASRT
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABSI alert in real time by email

     

    Gainers

    • Absci (NASDAQ:ABSI) stock increased by 28.2% to $7.87 during Friday's regular session. As of 12:30 EST, Absci's stock is trading at a volume of 38.6 million, which is 15366.1% of its average full-day volume over the last 100 days. The company's market cap stands at $728.6 million.
    • Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 15.8% to $2.02. Trading volume for Quoin Pharmaceuticals's stock is 41.2 million as of 12:30 EST. This is 3934.9% of its average full-day volume over the last 100 days. The company's market cap stands at $16.8 million.
    • Anixa Biosciences (NASDAQ:ANIX) shares increased by 15.06% to $3.36. Trading volume for this security as of 12:30 EST is 213.0K, which is 135.4% of its average full-day volume over the last 100 days. The company's market cap stands at $101.2 million. As per the news, the Q4 earnings report came out 3 days ago.
    • Assertio Holdings (NASDAQ:ASRT) shares rose 13.22% to $2.73. As of 12:30 EST, this security is trading at a volume of 1.4 million shares, making up 109.2% of its average full-day volume over the last 100 days. The company's market cap stands at $121.8 million.
    • Immuneering (NASDAQ:IMRX) stock rose 11.73% to $15.8. The market value of their outstanding shares is at $415.8 million.
    • CareMax (NASDAQ:CMAX) stock increased by 10.63% to $7.64. Trading volume for this security as of 12:30 EST is 105.9K, which is 44.7% of its average full-day volume over the last 100 days. The company's market cap stands at $665.6 million.
    •  

    Losers

    • Odonate Therapeutics (NASDAQ:ODT) stock fell 18.7% to $1.06 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 5.1 million shares, making up 715.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $40.9 million.
    • Alterity Therapeutics (NASDAQ:ATHE) shares fell 17.11% to $0.92. As of 12:30 EST, Alterity Therapeutics's stock is trading at a volume of 6.3 million, which is 277.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $36.9 million.
    • Ensysce Biosciences (NASDAQ:ENSC) shares declined by 13.69% to $4.1. Trading volume for Ensysce Biosciences's stock is 1.2 million as of 12:30 EST. This is 17.6% of its average full-day volume over the last 100 days. The company's market cap stands at $99.4 million.
    • Aligos Therapeutics (NASDAQ:ALGS) shares decreased by 13.51% to $3.97. Aligos Therapeutics's stock is trading at a volume of 895.6K shares as of 12:30 EST. This is 408.9% of its average full-day volume over the last 100 days. The company's market cap stands at $169.1 million.
    • Avalo Therapeutics (NASDAQ:AVTX) stock declined by 11.58% to $1.07. As of 12:30 EST, this security is trading at a volume of 1.6 million shares, making up 416.2% of its average full-day volume over the last 100 days. The company's market cap stands at $120.1 million.
    • Hoth Therapeutics (NASDAQ:HOTH) stock fell 11.21% to $0.95. The current volume of 1.5 million shares is 32.8% of Hoth Therapeutics's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $22.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABSI
    $ALGS
    $ANIX
    $ASRT

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Absci Corporation
    $ABSI
    1/8/2026$4.32Overweight → Equal-Weight
    Morgan Stanley
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    Immuneering Corporation
    $IMRX
    10/31/2025$15.00Outperform
    Leerink Partners
    Absci Corporation
    $ABSI
    10/2/2025Overweight
    Analyst
    Avalo Therapeutics Inc.
    $AVTX
    9/17/2025$15.00 → $25.00Buy
    H.C. Wainwright
    Avalo Therapeutics Inc.
    $AVTX
    9/5/2025Buy
    TD Cowen
    Aligos Therapeutics Inc.
    $ALGS
    8/18/2025$50.00Buy
    H.C. Wainwright
    More analyst ratings

    $ABSI
    $ALGS
    $ANIX
    $ASRT
    SEC Filings

    View All

    SEC Form S-8 filed by Aligos Therapeutics Inc.

    S-8 - Aligos Therapeutics, Inc. (0001799448) (Filer)

    3/5/26 8:28:14 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Aligos Therapeutics Inc.

    10-K - Aligos Therapeutics, Inc. (0001799448) (Filer)

    3/5/26 8:08:06 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aligos Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Aligos Therapeutics, Inc. (0001799448) (Filer)

    3/5/26 8:01:42 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABSI
    $ALGS
    $ANIX
    $ASRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Absci Corporation downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Absci Corporation from Overweight to Equal-Weight and set a new price target of $4.32

    1/8/26 8:35:39 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Mizuho initiated coverage on Avalo Therapeutics with a new price target

    Mizuho initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $39.00

    12/18/25 9:07:24 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ALGS
    $ANIX
    $ASRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pangalos Menelas N bought $205,760 worth of shares (75,095 units at $2.74), increasing direct ownership by 66% to 189,055 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/3/26 4:13:20 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Director Baskies Arnold M bought $30,400 worth of shares (10,000 units at $3.04), increasing direct ownership by 8% to 135,000 units (SEC Form 4)

    4 - Anixa Biosciences Inc (0000715446) (Issuer)

    1/29/26 8:58:38 AM ET
    $ANIX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Brakewood Harold Eugene bought $24,990 worth of shares (5,250 units at $4.76), increasing direct ownership by 91% to 11,050 units (SEC Form 4)

    4 - Immuneering Corp (0001790340) (Issuer)

    1/21/26 9:09:57 AM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ALGS
    $ANIX
    $ASRT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

    SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2025. "Our team has made tremendous progress recently in the global Phase 2 B-SUPREME study of pevifoscorvir sodium," stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "With the completion of the planned enrollment in the HBeAg- cohort, we are continuing to enroll participants in t

    3/5/26 8:00:00 AM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Hoth Therapeutics Deploys OpenAI API to Advance Development of Orphan HT-KIT Oncology Program

    AI Integration Supports IND Preparation & Phase 1 Progression for Rare KIT-Driven CancersNEW YORK, March 4, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company advancing breakthrough therapies for diseases, today announced the deployment of the OpenAI API to support IND-enabling development of HT-KIT, its orphan-designated therapy targeting rare and aggressive KIT-driven cancers. The OpenAI-powered API platform has been integrated into the HT-KIT development workflow to support preclinical data analysis, molecular modeling of K

    3/4/26 8:31:00 AM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

    MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured professor, Dr. Claassen will also retain his academic appointment at Vanderbilt University Medical Center. Dr. Claassen is a board-certified neurologist and internationally recognized expert in neurodegenerative diseases, with more than two decades of clinical and translational research in mov

    3/4/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ALGS
    $ANIX
    $ASRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Pangalos Menelas N was granted 5,800 shares, increasing direct ownership by 3% to 194,855 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/5/26 6:56:53 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Legal Officer Walker Shelby J. covered exercise/tax liability with 9,825 shares and was granted 90,300 shares, increasing direct ownership by 136% to 139,775 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/4/26 9:14:12 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Chief Executive Officer Mcclain Sean was granted 406,200 shares and covered exercise/tax liability with 25,316 shares, increasing direct ownership by 5% to 8,715,451 units (SEC Form 4)

    4 - Absci Corp (0001672688) (Issuer)

    3/4/26 9:05:13 PM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ABSI
    $ALGS
    $ANIX
    $ASRT
    Leadership Updates

    Live Leadership Updates

    View All

    Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

    MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured professor, Dr. Claassen will also retain his academic appointment at Vanderbilt University Medical Center. Dr. Claassen is a board-certified neurologist and internationally recognized expert in neurodegenerative diseases, with more than two decades of clinical and translational research in mov

    3/4/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer

    Former Vertex executive to spearhead the clinical development of Absci's expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci's Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer. Dr. Somaratne will spearhead the clinical development strategy and execution for Absci's expanding pipeline of AI-designed therapeutics. Dr. Somarat

    3/3/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

    − Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced − Highlights Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and comme

    1/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ALGS
    $ANIX
    $ASRT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Assertio Holdings Inc. on Jun 6

    Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition

    6/10/24 1:20:50 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ALGS
    $ANIX
    $ASRT
    Financials

    Live finance-specific insights

    View All

    Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026

    Assertio Holdings, Inc. ("Assertio") (NASDAQ:ASRT) today announced that it will release fourth quarter and full year 2025 financial results on Monday, March 16, 2026, after the market close. Following the release of its financial results, Assertio's management will host a live webcast of the earnings conference call at 4:30 p.m. Eastern Time. To access the live webcast, conference call information, and other materials, please visit Assertio's investor relations website at http://investor.assertiotx.com/overview/default.aspx. Please connect at least 10 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. For those wis

    3/3/26 4:30:00 PM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Absci to Report Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results on March 24, 2026

    VANCOUVER, Wash. and NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ:ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2025 after market close on Tuesday, March 24, 2026. Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook. Live audio of the webcast will be available on the company's investor relations website at: investors

    2/24/26 8:00:00 AM ET
    $ABSI
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

    - Reported 12-month overall survival (OS) in Phase 2a clinical trial nearly double the benchmark from pivotal study of standard of care gemcitabine/nab-paclitaxel (GnP) - - Atebimetinib consistently demonstrates impressive overall survival advantage at all time periods reported; Median overall survival remains unreached as of data cutoff, suggesting encouraging durability of clinical benefit - - Anticipate dosing first patient in pivotal Phase 3 clinical trial, MAPKeeper 301, in mid-2026 - - Company to host conference call at 4:30 p.m. ET today - NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping

    1/7/26 4:00:00 PM ET
    $IMRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABSI
    $ALGS
    $ANIX
    $ASRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 6:57:50 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Avalo Therapeutics Inc.

    SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

    11/14/24 6:23:00 PM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Aligos Therapeutics Inc.

    SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)

    11/14/24 6:19:11 PM ET
    $ALGS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care